Business
TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex® PRS for Plastic and Reconstructive Surgery
The OviTex PRS portfolio now includes a larger option than any human acellular dermal matrix product on the marketMALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on advancing soft-tissue reconstruction solutions, today announced the U.S. launch of larger sizes of OviTex PRS Reinforced Tissue Matrix, the only tissue-based device reinforced with polymer suture embroidery specifically engineered for plastic and re
About this update from Tela Bio, Inc.
[{"type":"image","alt":"TELA Bio, Inc.","displaySize":"","headline":null,"caption":"TELA Bio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":81,"url":"https://media.zenfs.com/en/globenewswire.com/8d626409a8c31e4dc7fea09f34dc0ef7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7TF7cdHGILp3Xeeqsee8gQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8d626409a8c31e4dc7fea09f34dc0ef7","width":300,"height":81}},"lazy":false},{"type":"text","content":"The OviTex PRS portfolio now includes a larger option than any human acellular dermal matrix product on the market","length":114,"tagName":"p"},{"type":"text","content":"MALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on advancing soft-tissue reconstruction solutions, today announced the U.S. launch of larger sizes of OviTex PRS Reinforced Tissue Matrix, the only tissue-based device reinforced with polymer suture embroidery specifically engineered for plastic and reconstructive surgery.","length":407,"tagName":"p"},{"type":"text","content":"Designed for consistency in thickness, stretch, permeability, and handling while facilitating functional remodeling,1 the OviTex PRS portfolio now includes expanded size offerings, including a 25 x 30 cm oval and a 25 cm diameter circle. These larger configurations may reduce the need for multiple smaller pieces and have the potential to simplify more complex plastic and reconstructive procedures.","length":400,"tagName":"p"},{"type":"text","content":"“The introduction of larger OviTex PRS sizes aligns with evolving trends in plastic and reconstructive surgery and strengthens the breadth of our offering in this space,” said Antony Koblish, Co-founder, President & CEO. “Since launching OviTex PRS in 2019 we have sold nearly 15,000 units, with year-over-year unit sales growth of 31% in 2024 alone. Plastic and reconstructive surgeons are increasingly seeking alternatives to cadaveric tissue, and this expansion reinforces our commitment to meet that demand.”","length":516,"tagName":"p"},{"type":"text","content":"“These new sizes directly address the needs expressed by our key opinion leaders and customers,” emphasized Dr. Howard Langstein, Vice President of Medical Affairs & Surgeon Strategy. “By...